Eribulin mesylate in the treatment of metastatic breast cancer

Sarika Jain; Tessa Cigler

首页> 外文期刊>Biologics: Targets and Therapy >Eribulin mesylate in the treatment of metastatic breast cancer

【24h】

Eribulin mesylate in the treatment of metastatic breast cancer

机译：Eribulin甲磺酸盐治疗转移性乳腺癌

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.

机译：随着治疗的主要目标包括延长毒性，治疗转移性乳腺癌（MBC）的治疗变得越来越具有挑战性。虽然多个药剂被批准用于MBC的治疗，但没有标准方法以超出二线的治疗方法。叶绿素甲磺酸盐，船只海绵卤氏素素B的类似物是非紫杉烷微管动态抑制剂，其具有与其他小管蛋白靶向药物不同的作用机制。基于在III期临床试验中出现的总体生存率的显着延伸，Eribulin在蒽环素和紫杉烷失败后批准了MBC患者的第三线治疗。 Eribulin具有可管理的毒性曲线和低发生的周围神经病变。在本综述中，我们讨论了Eribulin，药理学，作用方式，临床前和临床数据的自然来源，并以患者为重点的观点。

著录项

来源
《Biologics: Targets and Therapy》 |2012年第3期|共9页
作者
Sarika Jain; Tessa Cigler;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [J] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Trials . 2020,第1期

机译：Trastuzumab，Pertuzumab和Eribulin甲磺酸丁酯与曲妥珠单抗，Pertuzumab和紫罗兰作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势，III期的研究方案日本试验（JBCRG-M06 / Emerald）
2. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial [J] . Tetsu Hayashida, Hiromitsu Jinno, Katsuaki Mori, BMC Cancer . 2018,第1期

机译：Eribulin的II期试验是甲磺酸盐作为局部晚期或转移性乳腺癌的第一或第二线治疗：多中心，单臂试验
3. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study [J] . Shannon Puhalla, Sharon Wilks, Adam M Brufsky, Breast Cancer: Targets and Therapy . 2016,第1期

机译：先前的曲妥珠单抗联合甲磺酸艾瑞布林加曲妥珠单抗作为人表皮生长因子受体2阳性局部复发或转移性乳腺癌的一线治疗的临床效果：II期，单臂，多中心研究的结果
4. IG-001—A non-biologic micellar paclitaxel formulation for the treatment of metastatic Breast cancer [C] . Motamed Kouros, Hwang Larn, Hsiao Chao, IEEE International Conference on Nano/Molecular Medicine and Engineering . 2013

机译：IG-001—用于治疗转移性乳腺癌的非生物胶束紫杉醇制剂
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
7. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）
8. Fusion of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer. Addendum. [R] . Kufe, D. W. 2011

机译：乳腺癌和树突状细胞融合治疗转移性乳腺癌疫苗。附录。

Eribulin mesylate in the treatment of metastatic breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅